Whilst the current findings may benefit from further confirmatory evidence of CP exposure in patients with AD receiving therapeutic doses of CP, this study illustrates the importance of modelling and simulation for the characterization of the pharmacokinetics of topical drugs in dermatology. This evidence concerns the gene CP and Alzheimer disease.